All Releases
 |
Manhattan Pharmaceuticals Announces Amendment of Joint Venture Deal With Nordic Biotech
Jun 13, 2008
|
11.3 KB |
|
| |
NEW YORK, Jun 13, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that the FDA has directed Hedrin(tm), a novel, non-insecticide treatment for pediculosis (head lice), to the Center for Devices and Radiological Health (CDRH) division of the U.S. Food and Drug Administration (FDA) for revi...
|
|
Manhattan Pharmaceuticals to Present At Rodman & Renshaw 5th Annual Global Healthcare Conference
May 19, 2008
|
8.2 KB |
|
| |
NEW YORK, May 19, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that Douglas Abel, president and chief executive officer, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20 at 7:40 AM EDT (1:40 PM local time). The conference is being held May...
|
|
Manhattan Pharmaceuticals Announces Completion of Enrollment in Phase 2a Study of Topical PTH (1-34) for Psoriasis
Apr 10, 2008
|
10.5 KB |
|
| |
NEW YORK, Apr 10, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has completed patient enrollment in its ongoing Phase 2a clinical study of Topical PTH (1-34). This randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary e...
|
|
Manhattan Pharmaceuticals to Trade on OTCBB Under New Ticker Symbol MHAN
Mar 26, 2008
|
7.5 KB |
|
| |
NEW YORK, Mar 26, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has obtained a new ticker symbol, "MHAN". Effective immediately the company's common stock will begin trading under the new ticker symbol on the OTC Bulletin Board(r) (OTCBB), the over-the-counter equity securities ...
|
|
Manhattan Pharmaceuticals Successfully Completes Pre-IND Meetings for Altoderm and Altolyn
Mar 6, 2008
|
10.6 KB |
|
| |
NEW YORK, Mar 6, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has concluded successful pre-IND (Investigational New Drug) meetings with the U.S. Food and Drug Administration (FDA) and may file IND applications for both Altoderm(tm) and Altolyn(tm). The company intends to develop ...
|
|
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Feb 27, 2008
|
11.1 KB |
|
| |
NEW YORK, Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the closing of its joint venture agreement with Nordic Biotech Venture Fund II K/S (Nordic) to develop and commercialize Hedrin(tm), the company's novel, non-insecticide treatment for head lice for the North American market. ...
|
|
Manhattan Pharmaceuticals to Voluntarily Withdraw Its American Stock Exchange Common Stock Listing
Feb 22, 2008
|
10.7 KB |
|
| |
NEW YORK, Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has formally notified the American Stock Exchange ("AMEX") that it intends to voluntarily delist its common stock from AMEX. The company expects that the delisting will become effective within the next 25 calendar day...
|
|
Manhattan Pharmaceuticals to Present At the BIO CEO & Investor Conference 2008
Feb 8, 2008
|
7.7 KB |
|
| |
NEW YORK, Feb 8, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 12:30 PM ET. The conference is being held at Waldorf Astoria Hotel in New York C...
|
|
Manhattan Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Hedrin
Feb 5, 2008
|
10.5 KB |
|
| |
NEW YORK, Feb 5, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin™, the company's novel, non-insecticide treatment for head ...
|
|
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Dec 27, 2007
|
8.8 KB |
|
| |
NEW YORK, Dec 27, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the appointment of Mary C. Spellman, M.D. as its consultant Head of Dermatology and Drug Development. Dr. Spellman will oversee all aspects of clinical operations related to the development of Manhattan Pharmaceuticals' produ...
|
|
AMEX Accepts Manhattan Pharmaceuticals' Plan to Regain Compliance with Continued Listing Standards
Dec 10, 2007
|
7.3 KB |
|
| |
NEW YORK, Dec 10, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that the American Stock Exchange (AMEX) has accepted the Company's plan to regain compliance with continued listing standards of AMEX. The Company's plan was submitted in response to a letter from AMEX which informed the Company that it was not in ...
|
|
Manhattan Pharmaceuticals Announces Positive Clinical Results for Hedrin in Treatment of Head Lice
Nov 28, 2007
|
11.0 KB |
|
| |
NEW YORK, Nov 28, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the publication of positive clinical results for Hedrin(tm), the company's novel, non-insecticide product candidate for the treatment of head lice. These results appeared in the November issue of PLoS One, a leading internati...
|
|
Manhattan Pharmaceuticals to Present At Wall Street Analyst Forum
Nov 26, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 26, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Wall Street Analyst Forum on Wednesday, November 28, 2007, at 9:10 a.m. EST. The conference is being held at The Princeton Club in New York City.
...
|
|
Manhattan Pharmaceuticals to Present At Informed Investors Biotech/Pharma/Healthcare On-line Forum
Nov 12, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 12, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Informed Investors Biotech/Pharma/Healthcare On-line Forum on Tuesday, November 13, 2007 at 9:30 AM ET.
To access the audio webcast for this pr...
|
|
Webcast Alert: Biotech/Healthcare/Pharma On-line Forum (Manhattan Pharmaceuticals)
Nov 12, 2007
|
6.3 KB |
|
| |
NEW YORK, Nov 12, 2007 (BUSINESS WIRE) -- Webcast Alert: Biotech/Healthcare/Pharma On-line Forum
Manhattan Pharmaceuticals (AMEX:MHA) announces the following Webcast:
What: Biotech/Healthcare/Pharma On-line Forum
When: November 13, 2007 @ 9:30 AM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=122419
How: Live o...
|
|
Manhattan Pharmaceuticals to Present At Informed Investors Small Cap/Growth On-line Forum
Nov 7, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 7, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Informed Investors Small Cap/Growth On-line Forum on Thursday, November 8, 2007 at 10:30 AM ET.
To access the audio webcast for this presentatio...
|
|
Webcast Alert: Small Cap/Growth On-line Forum- Manhattan Pharmaceuticals
Nov 7, 2007
|
6.0 KB |
|
| |
NEW YORK, Nov 07, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals (AMEX:MHA) announces the following Webcast:
What: Small Cap/Growth On-line Forum
When: November 8, 2007 @ 10:30 AM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=122418
How: Live over the Internet -- Simply log on to the web at the address above.
...
|
|
Manhattan Pharmaceuticals to Present At the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Nov 2, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 2:20 PM ET. The conference is being held at The Palac...
|
|
Manhattan Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Topical PTH (1-34) for Psoriasis
Oct 31, 2007
|
10.3 KB |
|
| |
NEW YORK, Oct 31, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that the first patient has received the initial dose in their Phase 2a clinical study of the company's lead product candidate, topical PTH (1-34) for the treatment of psoriasis. This U.S. multi-center, randomized, double-blin...
|
|
Manhattan Pharmaceuticals to Present At Friedland Winter Life Sciences Conference
Oct 30, 2007
|
7.7 KB |
|
| |
NEW YORK, Oct 30, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Friedland Winter Life Sciences Conference on Thursday, November 1, 2007 at 9:59 AM ET. The conference is being held at the Double Tree Guest Suites...
|
|
|
